Area of research
Physiology · Immunology and Allergy
Research interest
Research focused on Asthma and Coronavirus disease 2019 (COVID-19), with related work in Grading (engineering), Pandemic, Benralizumab. Notable publications include 'Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision', 'Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised,...', and 'Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs'.
Concurrent validity, cut‐offs and ability to change of patient‐reported outcome measures for rhinitis and asthma in MASK‐air<sup>®</sup>
Idiopathic Pulmonary Fibrosis Is Associated with Common Genetic Variants and Limited Rare Variants
Development and validation of an electronic daily control score for asthma (e-DASTHMA): a real-world direct patient data study
Identification by cluster analysis of patients with asthma and nasal symptoms using the MASK-air® mHealth app
Development and Validation of an Electronic Daily Control Score for Asthma (e-DASTHMA)
Differentiation of COVID‐19 signs and symptoms from allergic rhinitis and common cold: An ARIA‐EAACI‐GA<sup>2</sup>LEN consensus
Intranasal corticosteroids in allergic rhinitis in COVID‐19 infected patients: An ARIA‐EAACI statement
Handling of allergen immunotherapy in the COVID‐19 pandemic: An ARIA‐EAACI statement
COVID‐19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper
ARIA‐EAACI statement on asthma and COVID‐19 (June 2, 2020)
Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence
<scp>ARIA</scp> pharmacy 2018 “Allergic rhinitis care pathways for community pharmacy”
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision
Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial
TBX4 is involved in the super-enhancer-driven transcriptional programs underlying features specific to lung fibroblasts
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs
Epithelial Cell-Derived IL-25, but Not Th17 Cell-Derived IL-17 or IL-17F, Is Crucial for Murine Asthma